期刊文献+

羟苯磺酸钙联合前列地尔治疗2型糖尿病周围神经病变疗效及安全性研究 被引量:5

Effects of calcicum dobesilated combined with alprostadil on diabetic peripheral neuropathy patients
原文传递
导出
摘要 目的探讨羟苯磺酸钙联合前列地尔治疗2型糖尿病周围神经病变的临床疗效。方法将2016年3—9月青岛市城阳区人民医院内分泌科住院的120例2型糖尿病周围神经病变患者随机分为两组。治疗组56例,给予前列地尔联合口服羟苯磺酸钙;对照组64例,仅给予前列地尔,两组均治疗2周。治疗前后进行密歇根糖尿病神经病变评分量表(MDNS)和密歇根神经病变筛查量表(MNSI)评分,观察两组之间临床表现改善和量表评分降低情况,并观察两组不良反应发生情况。结果治疗2周后,对照组和治疗组患者临床治疗总有效率分别为87.50%和96.43%,差异有统计学意义(χ2=16.802,P=0.000)。治疗2周后,治疗组MDNS和MNSI评分明显低于治疗前及对照组治疗后,差异有统计学意义(均P<0.05)。两组间不良反应发生率比较,差异均无统计学意义(P>0.05)。结论羟苯磺酸钙联合前列地尔治疗2型糖尿病周围神经病变的疗效优于单用前列地尔,且安全性好。 Objective To investigate the clinical effect of calcium dobesilate combined with alprostadil in the treatment of patients with type 2 diabetes mellitus(T2 DM)with diabetic peripheral neuropathy(DPN).Methods From March to September 2016,120 DPN patients in the Department of endocrinology of Chengyang District People’s Hospital of Qingdao were randomly divided into two groups:the treatment group(56 cases)was given alprostadil combined with oral calcium dobesilate;the control group(64 cases)was given alprostadil only.Both groups were treated for 2 weeks.Before and after treatment,the scores of the Michigan Diabetic Neuropathy Scale(MDNS)and the Michigan Neuropathy Screening Scale(MNSI)were used to observe the improvement of clinical performance and the decrease of scale scores between the two groups,and the adverse reactions between the two groups were observed.Results After 2 weeks of treatment,the total effective rate(96.43%)of the treatment group was significantly better than that(87.50%)of the control group(P=0.000,χ2=16.802).After 2 weeks of treatment,the scores of the MDNS and the MNSI in the treatment group were significantly lower than those before treatment and those in the control group after treatment(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Calcium dobesilate combined with alprostadil is more effective than alprostadil alone in the treatment of DPN without increasing adverse reactions.
作者 赵波 王琳 魏文娟 饶小胖 ZHAO Bo;WANG Lin;WEI Wen-juan;RAO Xiao-pang(Chengyang District People’s Hospital of Qingdao,Qingdao,Shandong 266109,China)
出处 《慢性病学杂志》 2020年第9期1317-1320,共4页 Chronic Pathematology Journal
关键词 羟苯磺酸钙 前列地尔 2型糖尿病 周围神经病变 Calcicum dobesilated Alprostadil Type 2 diabetes mellitus Diabetic peripheral neuropathy
  • 相关文献

参考文献3

二级参考文献40

  • 1Blindness caused by diabetes--Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep, 1996, 45:937-941.
  • 2Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Ham- man RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, WangN, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Me- ta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35:556-564.
  • 3Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic reti- nopathy in the adult population in China: the Beijing Eye Study 2001. Int Ophthalmol, 2009, 29:485-493.
  • 4Xu J, Wei WB, Yuan MX, Yuan SY, Wan G, Zheng YY, Li YB, Wang S, Xu L, Fu HJ, Zbu LX, Pu XL, Zhang JD, Du XP, Li YL, Ji Y, Gu XN, Li Y, Pan SF, Cui XL, Bai W, Chen YJ, Wang ZM, Zhu QS, Gao Y, Liu de Y, Ji YT, Yang Z, Jonas JB. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina, 2012, 32:322-329.
  • 5Wang FI-I, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, Sun LP, Friedman DS, Wang NL, Wong TY. Prevalence of diabetic retinopa- tby in rural China: the Handan Eye Study. Ophthalmology, 2009, 116 461 467.
  • 6ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363:233-244.
  • 7Vekasi J, Koltai K, Gaal V, Toth A, Juricskay I, Kesmarky G. The effect of aspirin on hemorheological parameters of patients with dia- betic retinopathy. Clin Hemorheol Microcirc, 2008, 39:385-389.
  • 8Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31: 2084-2094.
  • 9Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for ret- inopathy. Clin Sci (Lond), 2013, 124:597-615.
  • 10Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of an- tihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the Diabetic REtinopathy Candesartan Tri- als-Protect 2 study. J Hypertens, 2011, 29:1457-1462.

共引文献102

同被引文献46

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部